• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

英国肾脏注册处第18次年度报告(2015年12月)第5章:2014年接受肾脏替代治疗的英国成年患者的生存情况及死亡原因:全国及特定中心分析。

UK Renal Registry 18th Annual Report (December 2015) Chapter 5: Survival and Causes of Death in UK Adult Patients on Renal Replacement Therapy in 2014: National and Centre-specific Analyses.

作者信息

Steenkamp Retha, Rao Anirudh, Fraser Simon

机构信息

UK Renal Registry, Bristol, UK.

出版信息

Nephron. 2016;132 Suppl 1:111-44. doi: 10.1159/000444819. Epub 2016 Apr 19.

DOI:10.1159/000444819
PMID:27115403
Abstract

Survival of incident patients on RRT continued to improve over the last 14 years for both short and long term survival up to 10 years post RRT start. One year after 90 day age adjusted survival for incident RRT patients in the 2013 cohort increased to 91.4% from the previous year (91.0%); survival increased in incident patients aged ,65 years and in older patients (565 years). There was a difference in one year after 90 day incident survival by age group and diabetic status: diabetic patients aged ,65 years have slightly worse survival than non-diabetic patients, but survival for older diabetic patients (565 years) was significantly better than for non-diabetic patients. One year age adjusted survival for prevalent dialysis patients was 88.6% in the 2013 cohort, a slight decrease from the 2012 cohort (89.3%). Age adjusted one year survival for prevalent dialysis patients with diabetic primary renal disease has been declining slightly since 2012. Centre and UK country variability was evident in incident and prevalent patient survival after adjusting to age 60 and this finding would benefit from further investigation. The relative one year risk of death on RRT decreased with age from about 19 times that of the general population at age 35–39 years to 2.6 times at age 85 and over. In the prevalent RRT population, cardiovascular disease was the most common cause of death, accounting for 23% of deaths. Infection accounted for 20% of deaths and treatment withdrawal for 16% of deaths.

摘要

在过去14年中,接受肾脏替代治疗(RRT)的新发患者的短期和长期生存率(直至RRT开始后10年)持续改善。2013队列中,新发RRT患者90天年龄校正生存率在1年后从之前一年的91.0%升至91.4%;65岁及以下的新发患者和老年患者(≥65岁)的生存率均有所提高。90天新发患者1年后的生存率按年龄组和糖尿病状态存在差异:65岁及以下的糖尿病患者生存率略低于非糖尿病患者,但老年糖尿病患者(≥65岁)的生存率显著高于非糖尿病患者。2013队列中,长期透析患者1年年龄校正生存率为88.6%,较2012队列(89.3%)略有下降。自2012年以来,原发性肾病为糖尿病的长期透析患者的年龄校正1年生存率略有下降。在调整至60岁后,新发和长期患者的生存率在中心和英国各地区存在明显差异,这一发现值得进一步研究。RRT患者1年相对死亡风险随年龄下降,从35 - 39岁时约为普通人群的19倍降至85岁及以上时的2.6倍。在长期RRT人群中,心血管疾病是最常见的死亡原因,占死亡人数的23%。感染占死亡人数的20% , 治疗中断占死亡人数的16%。

相似文献

1
UK Renal Registry 18th Annual Report (December 2015) Chapter 5: Survival and Causes of Death in UK Adult Patients on Renal Replacement Therapy in 2014: National and Centre-specific Analyses.英国肾脏注册处第18次年度报告(2015年12月)第5章:2014年接受肾脏替代治疗的英国成年患者的生存情况及死亡原因:全国及特定中心分析。
Nephron. 2016;132 Suppl 1:111-44. doi: 10.1159/000444819. Epub 2016 Apr 19.
2
UK Renal Registry 13th Annual Report (December 2010): Chapter 6: survival and causes of death of UK adult patients on renal replacement therapy in 2009: national and centre-specific analyses.英国肾脏注册中心第 13 次年度报告(2010 年 12 月):第 6 章:2009 年英国成年接受肾脏替代治疗患者的生存和死亡原因:全国和中心特定分析。
Nephron Clin Pract. 2011;119 Suppl 2:c107-34. doi: 10.1159/000331756. Epub 2011 Aug 26.
3
UK Renal Registry 15th annual report: Chapter 5 survival and causes of death of UK adult patients on renal replacement therapy in 2011: national and centre-specific analyses.英国肾脏注册中心第 15 份年度报告:第 5 章 2011 年英国成年肾脏替代治疗患者的生存和死亡原因:全国和中心特定分析。
Nephron Clin Pract. 2013;123 Suppl 1:93-123. doi: 10.1159/000353324. Epub 2013 Jun 10.
4
UK Renal Registry 16th annual report: chapter 8 survival and cause of death of UK adult patients on renal replacement therapy in 2012: national and centre-specific analyses.英国肾脏登记处第 16 份年度报告:第 8 章 2012 年英国成年肾脏替代治疗患者的生存和死因:全国和中心特定分析。
Nephron Clin Pract. 2013;125(1-4):139-69. doi: 10.1159/000360027. Epub 2014 Feb 14.
5
UK Renal Registry 12th Annual Report (December 2009): chapter 7: survival and causes of death of UK adult patients on renal replacement therapy in 2008: national and centre-specific analyses.英国肾脏注册中心第 12 年度报告(2009 年 12 月):第 7 章:2008 年英国成年肾脏替代治疗患者的生存率和死亡原因:全国和中心特定分析。
Nephron Clin Pract. 2010;115 Suppl 1:c117-44. doi: 10.1159/000301162. Epub 2010 Mar 31.
6
UK Renal Registry 11th Annual Report (December 2008): Chapter 7 Survival and causes of death of UK adult patients on renal replacement therapy in 2007: national and centre-specific analyses.英国肾脏注册机构第11次年度报告(2008年12月):第7章2007年接受肾脏替代治疗的英国成年患者的生存率及死亡原因:全国性和特定中心分析
Nephron Clin Pract. 2009;111 Suppl 1:c113-39. doi: 10.1159/000209996. Epub 2009 Mar 26.
7
UK Renal Registry 17th Annual Report: Chapter 5 Survival and Cause of Death in UK Adult Patients on Renal Replacement Therapy in 2013: National and Centre-specific Analyses.英国肾脏注册处第17次年度报告:第5章 2013年接受肾脏替代治疗的英国成年患者的生存情况及死亡原因:全国及特定中心分析
Nephron. 2015;129 Suppl 1:99-129. doi: 10.1159/000370275. Epub 2015 Jan 22.
8
Chapter 6 Survival and causes of death of UK adult patients on renal replacement therapy in 2010: national and centre-specific analyses.第 6 章 2010 年英国成年肾脏替代治疗患者的生存和死亡原因:全国和中心特异性分析。
Nephron Clin Pract. 2012;120 Suppl 1:c105-35. doi: 10.1159/000342849. Epub 2012 Sep 1.
9
UK Renal Registry 12th Annual Report (December 2009): chapter 4: UK ESRD prevalent rates in 2008: national and centre-specific analyses.英国肾脏注册中心第 12 年度报告(2009 年 12 月):第 4 章:2008 年英国终末期肾病的流行率:全国和中心特定分析。
Nephron Clin Pract. 2010;115 Suppl 1:c41-67. doi: 10.1159/000301159. Epub 2010 Mar 31.
10
UK Renal Registry 15th annual report: Chapter 1 UK RRT incidence in 2011: national and centre-specific analyses.英国肾脏注册处第 15 次年度报告:第 1 章 2011 年英国 RRT 发病率:全国和中心特异性分析。
Nephron Clin Pract. 2013;123 Suppl 1:1-28. doi: 10.1159/000353320. Epub 2013 Jun 10.

引用本文的文献

1
A structured, home-based exercise programme in kidney transplant recipients (ECSERT): A randomised controlled feasibility study.肾移植受者的结构化家庭锻炼计划(ECSERT):一项随机对照可行性研究。
PLoS One. 2025 Feb 24;20(2):e0316031. doi: 10.1371/journal.pone.0316031. eCollection 2025.
2
Distinct Neutralising and Complement-Fixing Antibody Responses Can Be Induced to the Same Antigen in Haemodialysis Patients After Immunisation with Different Vaccine Platforms.在使用不同疫苗平台对血液透析患者进行免疫接种后,针对同一抗原可诱导出不同的中和抗体和补体结合抗体反应。
Vaccines (Basel). 2024 Dec 25;13(1):7. doi: 10.3390/vaccines13010007.
3
Evaluating Osteoporosis in Chronic Kidney Disease: Both Bone Quantity and Quality Matter.
评估慢性肾脏病中的骨质疏松症:骨量和骨质量都很重要。
J Clin Med. 2024 Feb 9;13(4):1010. doi: 10.3390/jcm13041010.
4
The high-volume haemodiafiltration vs high-flux haemodialysis registry trial (H4RT): a multi-centre, unblinded, randomised, parallel-group, superiority study to compare the effectiveness and cost-effectiveness of high-volume haemodiafiltration and high-flux haemodialysis in people with kidney failure on maintenance dialysis using linkage to routine healthcare databases for outcomes.高容量血液透析滤过与高通量血液透析登记试验(H4RT):一项多中心、非盲、随机、平行组、优效性研究,旨在比较使用常规医疗保健数据库进行结果链接的维持性透析患者中高容量血液透析滤过和高通量血液透析的有效性和成本效益。
Trials. 2022 Jun 27;23(1):532. doi: 10.1186/s13063-022-06357-y.
5
Availability of assisted peritoneal dialysis in Europe: call for increased and equal access.欧洲辅助性腹膜透析的供应情况:呼吁增加和公平获得。
Nephrol Dial Transplant. 2022 Oct 19;37(11):2080-2089. doi: 10.1093/ndt/gfac193.
6
Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021.成人糖尿病肾脏疾病患者的高血压和肾素-血管紧张素-醛固酮系统阻滞剂管理:英国临床糖尿病学家协会和英国肾脏协会 2021 年指南更新。
BMC Nephrol. 2022 Jan 3;23(1):9. doi: 10.1186/s12882-021-02587-5.
7
A pilot randomised controlled trial of a structured, home-based exercise programme on cardiovascular structure and function in kidney transplant recipients: the ECSERT study design and methods.一项针对肾移植受者心血管结构和功能的基于家庭的结构化运动方案的初步随机对照试验:ECSERT 研究设计和方法。
BMJ Open. 2021 Oct 5;11(10):e046945. doi: 10.1136/bmjopen-2020-046945.
8
Cost-effectiveness and value of information analysis of multiple frequency bioimpedance devices for fluid management in people with chronic kidney disease having dialysis.用于慢性肾病透析患者液体管理的多频生物阻抗设备的成本效益和信息分析价值
Cost Eff Resour Alloc. 2021 Apr 26;19(1):24. doi: 10.1186/s12962-021-00276-6.
9
Benefits and harms of high-dose haemodiafiltration versus high-flux haemodialysis: the comparison of high-dose haemodiafiltration with high-flux haemodialysis (CONVINCE) trial protocol.高剂量血液透析滤过与高通量血液透析的利弊:高剂量血液透析滤过与高通量血液透析的比较(CONVINCE)试验方案。
BMJ Open. 2020 Feb 5;10(2):e033228. doi: 10.1136/bmjopen-2019-033228.
10
A randomized controlled trial of different serum phosphate ranges in subjects on hemodialysis.一项针对血液透析患者不同血清磷范围的随机对照试验。
BMC Nephrol. 2019 Feb 4;20(1):37. doi: 10.1186/s12882-019-1216-2.